Last reviewed · How we verify
NCT06111911
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)
NA trial testing HPV Diagnostic Kit (Bio Farma) in Human Papilloma Virus Infection in 900 participants. Completed in 29 October 2022.
29 October 2022
Quick facts
| Lead sponsor | PT Bio Farma |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 900 |
| Start date | 1 April 2022 |
| Primary completion | 29 October 2022 |
| Estimated completion | 29 October 2022 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- HPV Diagnostic Kit (Bio Farma)
Conditions studied
- Human Papilloma Virus Infection — all drugs for Human Papilloma Virus Infection →
Sponsor
PT Bio Farma — full company profile →
Who can join
Adults 20 to 50, female only, with Human Papilloma Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a cross-sectional study to evaluate accuracy of high-risk DNA-HPV testing using HPV Diagnostic Kit (Bio Farma) compared to Standard Kit (COBAS® 6800 HPV from Roche Molecular Systems) RT-PCR based in urine and cervical swab specimens.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06111911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Papilloma Virus Infection
Currently open trials in the same condition.
- NCT06467942 — Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection · NA · recruiting
Other PT Bio Farma trials
Trials by the same sponsor.
- NCT06921460 — Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV · not yet recruiting
- NCT06690515 — Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in · Phase 1, PHASE2 · not yet recruiting
- NCT06690502 — Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination · completed
- NCT05933278 — Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine · Phase 2 · completed
- NCT06114641 — Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06111911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PT Bio Farma
- Last refreshed: 1 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06111911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing